

One of it's kind Case Simulation with self Assesment based Learning Module

Module 1 starts from Sun, 19th Dec, 2021

Module 2 starts from Sun, 23rd Jan, 2022

Module 3 starts from Sun, 13th Feb, 2022

Module 4 starts from Sun, 6th Mar, 2022

1

Every 75 Mins. Module will be active for 30 days.


8

Participants can attend the module at their convenient time

2



Supported by



Click on the link below for registration

Conceived and Managed by



3

https://www.onconxt.com/stepp



One of it's kind Case Simulation with self Assesment based Learning Module

Module 1 starts from Sun, 19th Dec, 2021

Module 2 starts from Sun, 23rd Jan, 2022

Module 3 starts from Sun, 13th Feb, 2022

Module 4 starts from Sun, 6th Mar, 2022

Dear Colleagues,

In recent years, prostate cancer management has become increasingly complex with new surgical techniques, radiotherapy, and the approval of several second-generation anti-androgen therapies. Moreover, clinical trials of targeted therapies, immunotherapies, and novel combination regimens are underway across various forms of the disease.

These case-based discussions highlight evidence from key trials on next-generation androgen-targeting agents, the role of DNA damage-response mutations, biomarker testing and the potential role of innovative targeted therapy, and advances in immunotherapy for prostate cancer. By providing a "roadmap" to the multiple pathways of prostate cancer management, this program serves as a resource for postgraduate students interested in the present and future applications of new science inpatient care.

Upon completion of this activity, participants should be better able to:

- Develop personalized, evidence-based treatment plans for patients in different prostate cancer settings with considerations of tumor, patient, and treatment-related factors
- Discuss newer advances in surgical and radiotherapy techniques.
- Discuss the clinical outcomes, latest guidelines, and expert recommendations for selection and sequencing of approved therapies, including hormonal, anti-androgen, cytotoxic, and bone-directed therapies, alone or in combination for non-metastatic and metastatic prostate cancers
- Assess the role of genetic testing for treatment decision-making through the prostate cancer disease continuum

Supported by



Click on the link below for registration

https://www.onconxt.com/stepp

Conceived and Managed by





Expert Faculty



Dr. Jagdeesh N Kulkarni Director Minimal Invasive & Robotic Surgery, Prof & Head, Dept of GU/GYN Oncology, ACI - Cumballa Hills Hospital, Mumbai



Dr. Tejinder Singh Sr. Consultant Medical Oncologist, Apollo Hospitals, Mumbai



Dr. Vivek Venkat Sr. Consultant - Urology & Robotic Urology Nanavati Max Super Speciality Hospital Mumbai



Dr. Santosh Waigankar Consultant, Uro-Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai



Dr. Kaustav Talapatra Director, Radiation Oncologist, Nanavati Max Super Speciality Hospital Mumbai





Dr. G.V.K. Reddy Sr. Consultant Medical Oncologist, Yashoda Hospital, Hyderabad

Dr. Adwaita Gore Associate Director Medical Oncology Nanavati Max Super Speciality Hospital Mumbai

Supported by



Click on the link below for registration

https://www.onconxt.com/stepp

Conceived and Managed by





One of it's kind Case Simulation with self **Assesment based Learning Module**

Module 3: Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Start date: 13th Feb 2022 | End date: 13th Mar 2022

Each 75 minutes Module will be active for 30 days. Participants can attend the Module at their convenient time

| TIME | TOPIC |
|----------------|---|
| 7:00 - 7:30 pm | Understanding the Evolving Treatment Landscape in Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
| 7:30 - 7:45 pm | Audience Participation in Case Simulation |
| 7:45 - 8:15 pm | Case Base Discussion (mCRPC) |

Steps to complete Module 2: Metastatic Hormone Sensitive Prostate Cancer (mHSPC)



Understanding the Evolving Treatment Landscape in Metastatic Castrate **Resistant Prostate Cancer (mCRPC)** (Medical Oncologist Perspective)




Participates in case simulation

Expert prospective on the case

Self Assesment

Download Certificate

Supported by



Click on the link below for registration

https://www.onconxt.com/stepp

Conceived and Managed by





One of it's kind Case Simulation with self Assesment based Learning Module

Each 75 minutes Module will be active for 30 days. Participants can attend the Module at their convenient time

Module 4 starts on Sun, 6th March, 2022

| TIME | TOPIC |
|----------------|--|
| 7:00 - 7:30 pm | Role of Genetic testing in Prostate Cancer |
| 7:30 - 7:45 pm | Audience Participation in Case Simulation |
| 7:45 - 8:15 pm | Case Base Discussion (HRR Mutation) |

Concept conceived, developed and managed by




Dr. Jainam Jain

Webinar Manager, River Route Event, Mumbai M: +91 88888 91624 E: rrcg.drjainam@gmail.com

Requesting you to share this brochure and link with your colleagues and students

Supported by



Click on the link below for registration

Conceived and Managed by



https://www.onconxt.com/stepp